Internal Server Error

Corelia Bio - About the company

Corelia Bio is an unfunded company based in Gottingen (Germany), founded in 2026. It operates as a Developer of engineered human tissue models for cardio-renal research. Corelia Bio has not raised any funding yet. The company has 541 active competitors, including 171 funded and 85 that have exited. Its top competitors include companies like MedGenome, Aspen Neuroscience and Biocytogen.

Company Details

Developer of engineered human tissue models for cardio-renal research. This organization creates systems that simulate chronic kidney disease and associated cardiac injury to investigate biological mechanisms and drug responses. It provides a research platform that utilizes artificial intelligence to organize evidence and assist in framing study questions for translational development programs. The technology enables the evaluation of contractility, structural remodeling, and molecular signaling within engineered myocardial modules.
Key Metrics
Founded Year
2026
Location
Gottingen, Germany
Stage
Unfunded
Ranked
690th among 690 competitors
Similar Companies
Sign up to download Corelia Bio's company profile

Corelia Bio's funding and investors

Corelia Bio has not raised any funding rounds yet.

chrome_extension_cta_illustration
Access Tracxn on any website
Our Google Chrome extension lets you view company details while browsing their websites
Install Tracxn Extension

Corelia Bio's Competitors and alternates

Top competitors of Corelia Bio include MedGenome, Aspen Neuroscience and Biocytogen. Here is the list of Top 10 competitors of Corelia Bio, ranked by Tracxn score:
Rank
Company Details
Short Description
Total Funding
Investors
Tracxn Score
1st
Logo for MedGenome
MedGenome
2013, Bengaluru (India), Series E
Provider of DNA sequencing, bioinformatics, and multiomics services
$264M
70/100
2nd
Logo for Aspen Neuroscience
Aspen Neuroscience
2018, San Diego (United States), Public
Provider of genomic-based personalised pluripotent stem cell therapy
$339M
69/100
3rd
Logo for Biocytogen
Biocytogen
2008, Wakefield (United States), Public
Provider of integrated solutions for next-generation antibody drug development
$301M
69/100
4th
Logo for Personalis
Personalis
2011, Menlo Park (United States), Acquired
Provider of genomic sequencing and diagnosis software for the healthcare industry
$87.3M
68/100
5th
Logo for Caris Life Sciences
Caris Life Sciences
1996, Irving (United States), Public
Developer of panomic disease profiling technologies for cancer precision medicine
$1.23B
67/100
6th
Logo for Applied StemCell
Applied StemCell
2008, Milpitas (United States), Acquired
Provider of animal and cell line models as tools for drug discovery and diagnostics
$67.5M
66/100
7th
Logo for Pandorum
Pandorum
2011, Bengaluru (India), Series B
Developer of regenerative medicine and 3D tissues
$52.1M
65/100
8th
Logo for InSphero
InSphero
2009, Schlieren (Switzerland), Series D
Developer of cell based assays for drug screening
$35M
64/100
9th
Logo for Blue Rock Therapeutics
Blue Rock Therapeutics
2016, Boston (United States), Acquired
Stem cell therapies for cardiovascular and neurological diseases
$225M
64/100
10th
Logo for UniQure
UniQure
1998, Amsterdam (Netherlands), Public
Developer of gene-based therapies for patients with genetic or acquired diseases
$111M
63/100
690th
Logo for Corelia Bio
Corelia Bio
2026, Gottingen (Germany), Unfunded
Developer of engineered human tissue models for cardio-renal research
-
-
-
lockGet insights and benchmarks for competitors of 2M+ companies! Sign up today!
Looking for more details on Corelia Bio's competitors? Click here to see the top ones

Corelia Bio's Investments and acquisitions

Corelia Bio has made no investments or acquisitions yet.

Reports related to Corelia Bio

Here is the latest report on Corelia Bio's sector:

FAQs about Corelia Bio

Explore our recently published companies
Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford